Trade

with

Isis Pharmaceuticals
(NASDAQ: ISIS)
AdChoices
40.48
-0.64
-1.56%
After Hours :
40.63
+0.15
+0.37%

Open

41.20

Previous Close

41.12

Volume (Avg)

1.55M (2.01M)

Day's Range

40.22-41.66

52Wk Range

22.25-62.66

Market Cap.

4.77B

Dividend Rate ( Yield )

-

Beta

1.48

Shares Outstanding

117.74M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 147.28M

    • Net Income

    • -60.64M

    • Market Cap.

    • 4.77B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -61.04

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.48

    • Forward P/E

    • -35.21

    • Price/Sales

    • 31.25

    • Price/Book Value

    • 12.99

    • Price/Cash flow

    • -312.50

      • EBITDA

      • -37.42M

      • Return on Capital %

      • -11.48

      • Return on Equity %

      • -24.01

      • Return on Assets %

      • -11.48

      • Book Value/Share

      • 3.12

      • Shares Outstanding

      • 117.74M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 60.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -1.15

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 49.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 6.56

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -65.05

            • 39.38

            • Net Profit Margin

            • -61.04

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -57.30

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -24.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.63

              • 0.76

              • Current Ratio

              • 7.00

              • 2.92

              • Quick Ratio

              • 6.28

              • 2.35

              • Interest Coverage

              • -4.00

              • 38.02

              • Leverage Ratio

              • 2.23

              • 2.21

              • Book Value/Share

              • 3.12

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -50.51

                • 277.78

                • P/E Ratio 5-Year High

                • -79.22

                • 634.30

                • P/E Ratio 5-Year Low

                • -7.90

                • 124.82

                • Price/Sales Ratio

                • 30.77

                • 9.35

                • Price/Book Value

                • 12.79

                • 8.50

                • Price/Cash Flow Ratio

                • -312.50

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -24.01

                    (-7.20)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -11.48

                    (-4.60)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -11.97

                    (-8.30)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.19

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -51.67M
                  Operating Margin
                  -35.08
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -312.50
                  Ownership

                  Institutional Ownership

                  99.31%

                  Top 10 Institutions

                  58.39%

                  Mutual Fund Ownership

                  64.02%

                  Float

                  84.86%

                  5% / Insider Ownership

                  0.26%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Growth Company Fund

                  •  

                    8,678,597

                  • 0.00

                  • 7.37

                  • Bb Biotech AG

                  •  

                    6,706,526

                  • 6.43

                  • 5.70

                  • Artisan Mid Cap Fund

                  •  

                    3,255,236

                  • -1.94

                  • 2.76

                  • AZ InvestEd Ivy Science & Tech Fund

                  •  

                    2,973,300

                  • 21.17

                  • 2.53

                  • Ivy Science and Technology Fund

                  •  

                    2,973,300

                  • 0.00

                  • 2.53

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    2,384,987

                  • 0.00

                  • 2.03

                  • Fidelity® Series Growth Company Fund

                  •  

                    2,088,785

                  • 0.00

                  • 1.77

                  • Vanguard Small Cap Index

                  •  

                    2,045,055

                  • -0.20

                  • 1.74

                  • Waddell & Reed Advisor Science And Techn

                  •  

                    2,030,600

                  • 0.00

                  • 1.73

                  • Legg Mason ClearBridge US Aggressive Gr

                  •  

                    1,917,130

                  • 0.00

                  • 1.63

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    17,549,733

                  • 0.00%

                  • 14.91

                  • ClearBridge Advisors, LLC

                  •  

                    8,239,358

                  • +12.19%

                  • 7.00

                  • Artisan Partners Limited Partnership

                  •  

                    7,571,076

                  • -13.59%

                  • 6.43

                  • Vanguard Group, Inc.

                  •  

                    7,269,544

                  • -6.64%

                  • 6.18

                  • Bellevue Asset Management AG

                  •  

                    6,706,526

                  • +6.43%

                  • 5.70

                  • BB Biotech AG

                  •  

                    6,706,526

                  • +6.43%

                  • 5.70

                  • Waddell & Reed Investment Management Co

                  •  

                    5,363,800

                  • +0.92%

                  • 4.56

                  • BlackRock Fund Advisors

                  •  

                    4,133,698

                  • -5.69%

                  • 3.51

                  • T. Rowe Price Associates, Inc.

                  •  

                    2,766,278

                  • -14.34%

                  • 2.35

                  • State Street Corp

                  •  

                    2,407,618

                  • -0.01%

                  • 2.05

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Mid Growth

                  Isis Pharmaceuticals was incorporated in California in 1989, and in January 1991 the Company changed its state of incorporation to Delaware. The Company is engaged in antisense drug discovery and development, exploiting a novel drug ...morediscovery platform it created to generate a pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs. The Company business consists of Drug Discovery and Development operations. Its flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH. Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies. ...moreThe Company has a pipeline of 31 drugs in development. Company’s ISIS-TTR and ISIS-SMN drugs are in late stage development. Its partners include Biogen Idec, AstraZeneca and Roche. The Company’s drugs compete with existing therapies for market share. It also competes with specialized pharmaceutical firms and large pharmaceutical companies acting either independently or together with biopharmaceutical companies. The Company is subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations.lessless

                  Key People

                  Dr. Stanley T. Crooke,M.D.,PhD

                  CEO/Chairman of the Board/Director/Founder/President

                  Ms. Elizabeth L. Hougen

                  CFO/Senior VP, Divisional

                  D. Wade Walke, PhD

                  Vice President, Divisional

                  Ms. B. Lynne Parshall, J.D.

                  COO/Director/Secretary

                  Mr. Joseph H. Wender

                  Director

                  • Isis Pharmaceuticals

                  • 2855 Gazelle Court

                  • Carlsbad, CA 92010

                  • USA.Map

                  • Phone: +1 760 931-9200

                  • Fax: -

                  • isispharm.com

                  Incorporated

                  1989

                  Employees

                  365

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: